251 related articles for article (PubMed ID: 26761785)
1. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study.
Ribal MJ; Mengual L; Lozano JJ; Ingelmo-Torres M; Palou J; Rodríguez-Faba O; Witjes JA; Van der Heijden AG; Medina R; Conde JM; Marberger M; Schmidbauer J; Fernández PL; Alcaraz A
Eur J Cancer; 2016 Feb; 54():131-138. PubMed ID: 26761785
[TBL] [Abstract][Full Text] [Related]
2. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
3. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
4. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic predictive value of Xpert Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer.
D Elia C; Pycha A; Folchini DM; Mian C; Hanspeter E; Schwienbacher C; Vjaters E; Pycha A; Trenti E
J Clin Pathol; 2019 Feb; 72(2):140-144. PubMed ID: 30355587
[TBL] [Abstract][Full Text] [Related]
7. Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study.
Han C; Mengual L; Kang B; Lozano JJ; Yang X; Zhang C; Alcaraz A; Liang J; Ye D
J Cancer; 2018; 9(17):3208-3215. PubMed ID: 30210644
[No Abstract] [Full Text] [Related]
8. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
10. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
[TBL] [Abstract][Full Text] [Related]
11. Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
Du L; Duan W; Jiang X; Zhao L; Li J; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Yang Y; Wang C
J Cell Mol Med; 2018 May; 22(5):2838-2845. PubMed ID: 29516641
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
[TBL] [Abstract][Full Text] [Related]
13. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
[TBL] [Abstract][Full Text] [Related]
14. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance and utility of a NNMT-based urine test for bladder cancer.
Pozzi V; Di Ruscio G; Sartini D; Campagna R; Seta R; Fulvi P; Vici A; Milanese G; Brandoni G; Galosi AB; Montironi R; Cecati M; Emanuelli M
Int J Biol Markers; 2018 Jan; 33(1):94-101. PubMed ID: 29148015
[TBL] [Abstract][Full Text] [Related]
16. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
[TBL] [Abstract][Full Text] [Related]
17. UriBLAD: A Urine-Based Gene Expression Assay for Noninvasive Detection of Bladder Cancer.
Wang Q; Hu L; Ma W; Meng Z; Li P; Zhang X; Wang Y; Lu Y; Sun Y; Wu Y; Ren W; Song K; Chen J; Wu S; Xu Q; Huang D; Zhang D; Shen Y; Ye D
J Mol Diagn; 2021 Jan; 23(1):61-70. PubMed ID: 33122139
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
19. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
20. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
Duan W; Du L; Jiang X; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Zhang X; Pan H; Yang Y; Wang C
Oncotarget; 2016 Nov; 7(48):78850-78858. PubMed ID: 27793008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
